Advertisement

Wiener klinische Wochenschrift

, Volume 131, Issue 1–2, pp 47–47 | Cite as

Correction to: Ruxolitinib therapy formyelofibrosis in Austria

Consensus on therapy management
  • Maria-Theresa KrauthEmail author
  • Sonja Burgstaller
  • Veronika Buxhofer-Ausch
  • Günther Gastl
  • Klaus Geissler
  • Felix Keil
  • Peter Krippl
  • Thomas Melchardt
  • Andreas Petzer
  • Holger Rumpold
  • Thamer Sliwa
  • Stefan Wöhrer
  • Albert Wölfler
  • Heinz Gisslinger
Correction
  • 246 Downloads

Correction to:

Wien Klin Wochenschr 2018

 https://doi.org/10.1007/s00508-018-1365-5

The original version of this article unfortunately contained a mistake. Table Nr. 1 was inconsistent. The corrected version of Table 1 is given below. We apologize for any inconveniences this may have caused.
Table 1

World Health Organisation (WHO) diagnostic criteria for PMF. (Table adjusted from [20])

WHO diagnostic criteria for PMF

I. Major criteria

a. Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3

b. Not meeting WHO criteria for BCR-ABL1+ chronic myelogenous leukemia, essential thrombocythemia, polycythemia vera, myelodysplastic syndromes, or other myeloid neoplasms

c. Demonstration of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence of another clonal markera, or no evidence of reactive bone marrow fibrosis

II. Minor criteria

a. Anemia not attributed to a comorbid condition

b. Leukocytosis ≥11 × 109/l

c. Palpable splenomegaly

d. Serum lactate dehydrogenase increased to above upper limit of normal

e. Leukoerythroblastosis

For meeting the requirement of PMF, all 3 major criteria, plus ≥1 minor criterion (confirmed in 2 consecutive determinations) must be met

aIn absence of any of the three major clonal mutations, analysis of the most frequent accompanying mutations (e. g. ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, SF3B1) can be valuable

Copyright information

© The Author(s) 2018 2018

Authors and Affiliations

  • Maria-Theresa Krauth
    • 1
    Email author
  • Sonja Burgstaller
    • 2
  • Veronika Buxhofer-Ausch
    • 3
  • Günther Gastl
    • 4
  • Klaus Geissler
    • 5
  • Felix Keil
    • 6
  • Peter Krippl
    • 7
  • Thomas Melchardt
    • 8
  • Andreas Petzer
    • 3
  • Holger Rumpold
    • 9
  • Thamer Sliwa
    • 6
  • Stefan Wöhrer
    • 10
  • Albert Wölfler
    • 11
  • Heinz Gisslinger
    • 1
  1. 1.Department of Internal Medicine I, Division of Hematology and HemostaseologyMedical University ViennaViennaAustria
  2. 2.Department of Internal Medicine IVKlinikum Wels-GrieskirchenWelsAustria
  3. 3.Department of Internal Medicine I, Hematology with Stem Cell Transplantation, Hemostaseology and Medical OncologyOrdensklinikum Linz-ElisabethinenLinzAustria
  4. 4.Department of Internal Medicine V, Division Hematology and OncologyMedical University of InnsbruckInnsbruckAustria
  5. 5.Fifth Medical DepartmentHospital HietzingViennaAustria
  6. 6.Third Medical DepartmentHanusch HospitalViennaAustria
  7. 7.Department of Internal Medicine, LKH FürstenfeldKrankenhausverbund FeldbachFürstenfeldAustria
  8. 8.Third Medical Department, Division Hematology and Medical OncologyParacelsus Medical University SalzburgSalzburgAustria
  9. 9.Internal Medicine II, Medical Oncology, Hematology, Gastroenterology and RheumatologyAcademic Teaching Hospital FeldkirchFeldkirchAustria
  10. 10.Permedio Center for Personalized Medicine and Sanatorium Hera ViennaViennaAustria
  11. 11.Division of HematologyMedical University of GrazGrazAustria

Personalised recommendations